Supplementary Tables and Figures from Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes
crossref(2023)
摘要
Supp Tables and Figs
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
crossref(2023)
Supp Tables and Figs